The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma
European Journal of Epidemiology · 2025-01 · 40 (1) · 27-42
DOI: 10.1007/s10654-024-01188-4 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Epidemiology, online erschienen am 09.01.2025. Verfasst von Catherine Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health~Holland, KWF Kankerbestrijding.
Abstract (Originalsprache)
Early-stage cutaneous melanoma patients generally have a favorable prognosis, yet a significant proportion of metastatic melanoma cases arise from this group, highlighting the need for improved risk stratification using novel prognostic biomarkers. The Dutch Early-Stage Melanoma (D-ESMEL) study introduces a robust, population-based methodology to develop an absolute risk prediction model for stage I/II melanoma, incorporating clinical, imaging, and multi-omics data to identify patients at increased risk for distant metastases. Utilizing the Netherlands Cancer Registry and Dutch Nationwide Pathology Databank, we collected primary tumor samples from early-stage melanoma patients, with and without distant metastases during follow-up. Our study design includes a discovery set of metastatic cases and matched controls to identify novel prognostic factors, followed by a validation cohort using a nested case–control design to validate these factors and to build a risk prediction model. Tissue sections underwent Hematoxylin & Eosin (H&E) staining, RNA sequencing (RNAseq), DNA sequencing (DNAseq), immunohistochemistry (IHC), and multiplex immunofluorescence (MxIF).The discovery set included 442 primary melanoma samples (221 case–control sets), with 46% stage I and 54% stage II melanomas. The median time to distant metastasis was 3.4 years, while controls had a median follow-up time of 9.8 years. The validation cohort included 154 cases and 154 controls from a random population-based selection of 5,815 patients. Our approach enabled the collection of a large number of early-stage melanoma samples from population-based databases with extensive follow-up and a sufficient number of metastatic events. This methodology in prognostic cancer research holds the potential to impact clinical decision-making through absolute risk prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
- Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Dutch Nationwide Pathology Databank (Palga), Houten, The Netherlands.
- Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. l.hollestein@erasmusmc.nl.
Förderung
- Health~Holland
- KWF Kankerbestrijding
Zitieren
APA
Zhou, C., Mooyaart, A. L., Kerkour, T., Louwman, M. W. J., Wakkee, M., Li, Y., Voorham, Q. J. M., Bruggink, A., Nijsten, T. E. C., & Hollestein, L. M. (2025). The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. European Journal of Epidemiology, 40(1), 27-42. https://doi.org/10.1007/s10654-024-01188-4
Vancouver
Zhou C, Mooyaart AL, Kerkour T, Louwman MWJ, Wakkee M, Li Y, et al. The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. European Journal of Epidemiology. 2025;40(1):27-42. doi:10.1007/s10654-024-01188-4
BibTeX
@article{Zhou2025,
author = {Zhou, Catherine and Mooyaart, Antien L and Kerkour, Thamila and Louwman, Marieke W J and Wakkee, Marlies and Li, Yunlei and Voorham, Quirinus J M and Bruggink, Annette and Nijsten, Tamar E C and Hollestein, Loes M},
title = {The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma},
journal = {European Journal of Epidemiology},
year = {2025},
volume = {40},
number = {1},
pages = {27--42},
doi = {10.1007/s10654-024-01188-4}
}
EUVIMED